Safety data indicate mostly mild gastrointestinal events (nausea, diarrhea, vomiting), dose-dependent, and often improved with titration
Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges
Our experienced practitioners will guide you on how to self-administer the injections, ensuring ease and convenience
For a 250-pound individual, 28.7% body weight loss translates to roughly 71 pounds
The European Medicines Agency has recommended updating drug labels for semaglutide to include NAION as a very rare side effect, advising patients to seek immediate medical care if sudden vision changes occur
